ABSTRACT
Objective: To explore the accurate measurement of endoscopic submucosal dissection (ESD) resected specimens of the digestive tract and the method of drawing the restoration map. Methods:From February to September 2018, 54 cases of digestive tract mucosa specimens were removed by ESD in the Department of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University. After standardized fixing, cutting, slide making and reading, Adobe Photoshop (PS) software was used to synthesize the slides and gross images. Synthesis data were measured using Digitimizer software, and the restoration map was drawn. Results: There were two types of restoration map drawing results. One was the surface plane distribution map of the lesion (that is, the ordinary restoration map) and 54 cases of this group were drawn with standard progress. The other was the section map of the lesion, and one case of colorectal adenoma with high-grade lesions was used to map and measure the distribution of the lesion. The size of 54 ESD specimens was measured, the minimum was 11.0 mm, the maximum was 93.5 mm, the median size was 33.2 mm, the lesion size was 0.9-45.7 mm, and the median size was 23.3 mm. The horizontal margin (PHM) showed positive in 9 cases, of which 4 cases were positive in early-stage cancer, and the negative margin showed a distance of 0.2-11.5 mm and a median position of 5.9 mm. Conclusion: This study combines PS's powerful image synthesis technology and Digimizer's professional image measurement technology to solve the computational ratio problem in ESD restoration map production process, and provides a practical reference method for drawing various complex restoration maps.
ABSTRACT
This article reports a female type Ⅱ Lynch syndrome patient who suffered from colon cancer and endometrium carcinoma consecutively. We also briefly elucidate the pathogenesis,clinicopathological features,screening,and management of Lynch syndrome. Regular screening and early diagnosis and treatment may help to reduce the incidences and mortality rates of tumors associated with Lynch syndrome.
ABSTRACT
Purpose To investigate the frequency of anaplastic lymphoma kinase (ALK) expression in non-small cell lung cancer (NSCLC) patients and its correlation with the clinicopathologic features.Methods 1 047 cases of non-small cell lung cancer diagnosed by pathological examination were enrolled in this study.The status of ALK was detected by Ventana anti ALK reagent and IHC staining,and the clinical characteristics and pathological features of ALK gene were analyzed.Results Among 1 047 patients with non-small cell lung cancer,there are 72 cases with positive ALK (6.88％).These cases included 70 cases of adenocrcinoms and 2 adenosquamous carcinomas,with 40 males and 32 females,or 37 smokers and 35 non-smokers.The median age was 56 years and the mean age was 55.60 years.Histopathologically,43 cases were solid predominant adnocarcinomas,16 cases were acinar predominant adenocarcinomas,and 13 cases were papillary predominant adenocarcinomas.None were lepidic predominant adenocarcinomas.Conclusion ALK gene fusion lung cancer is a new molecular subtype of nonsmall cell lung cancer.It has unique clinical feature and pathological morphology.Ventana anti ALK reagent and IHC staining method are the first choice for the test of ALK positive non-small cell lung cancer,which has important significance to improve the detection rate and individual treatment for this type of lung cancer.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the expressions of FOXC1 and matrix metalloproteinase 7 (MMP-7) in different molecular subtypes of breast cancer and their association with clinicopathological characteristics of the disease.</p><p><b>METHODS</b>Based on immunohistochemical results of ER, PR, HER2, CK5/6, CK14 and EGFR, 105 breast cancer patients were classified as 4 subtypes: luminal, HER2 positive, basal-like subtype (BLs) and normal breast-like subtype (NBLs). The association of FOXC1 and MMP-7 expressions with clinicopathological parameters in different molecular subtypes was analyzed.</p><p><b>RESULTS</b>Out of 105 patients with breast cancer, the subtypes of luminal, HER2 positive, BLs and NBLs accounted for 52.4% (55/105), 16.2% (17/105), 17.1%(18/105) and 14.3% (15/105), respectively. Patients with luminal and/or NBLs subtypes had significantly higher 5-year survival rate than those with HER2 positive and/or BLs did (log-rank=22.161, P<0.01). The overall positive expression rate of FOXC1 was 26.7% (28/105) and the expression was higher in BLs patients than that in other subgroups (χ²=30.108, P<0.01). The expression of FOXC1 was correlated with histological grade, tumor size, distant metastasis and 5-year survival rate of breast cancer. The overall positive expression rate of MMP-7 was 67.6% (71/105) and the expression of MMP-7 was also higher in BLs patients than that in other molecular subtypes (χ²=11.328, P<0.05). The positive expression of MMP-7 was correlated with metastasis in ipsilateral axillary lymph nodes, distant metastasis and 5-year survival rate of the patients. FOXC1 was correlated with MMP-7 (r=0.325, P<0.01).</p><p><b>CONCLUSION</b>Patients with luminal and/or NBLs breast cancer have more favorable prognosis than those with HER2 positive and/or BLs subtypes. The expressions of FOXC1 and MMP-7 are closely correlated with the clinicopathological features of breast cancer patients.</p>